Jones Trading has initiated coverage on AbCellera Biologics (ABCL) with an optimistic view, drawing fresh attention to the antibody drug developer and prompting investors to reassess the stock’s risks, pipeline, and recent share performance.
See our latest analysis for AbCellera Biologics.
At a share price of US$3.54, AbCellera Biologics has seen a 2.91% 1 day share price return and a 90 day share price return decline of 18.99%, while the 1 year total shareholder return of 47.5% contrasts with a 3 year total shareholder return decline of 52.03%. This suggests momentum has improved recently even as longer term holders remain under pressure.
If this kind of renewed interest in AbCellera has your attention, it could be a moment to see what else is setting the pace among healthcare related AI names with the 31 healthcare AI stocks
With AbCellera trading at US$3.54 and analysts’ average target sitting much higher at US$9.17, the key question is simple: are you looking at a discounted entry, or is the market already pricing in future growth?
Most Popular Narrative: 64% Undervalued
With AbCellera Biologics last closing at $3.54 against a narrative fair value of $9.83, the current price sits well below what this widely followed model suggests.
The completion of AbCellera's integrated clinical manufacturing capabilities by the end of 2025 is likely to enhance operational efficiency and reduce COGS, potentially improving net margins as the company begins utilization of these capabilities. Financial backing with over $630 million in liquidity and additional funding commitments provides AbCellera with the necessary resources to support long-term pipeline development, enhancing potential future earnings through successful commercialization of their clinical candidates.
Curious what kind of revenue ramp and margin profile need to line up for that $9.83 fair value to make sense? The narrative leans on aggressive revenue compounding, a turn toward positive margins, and a rich future earnings multiple that is usually reserved for market favorites. Want to see exactly which assumptions carry the most weight in that equation? The full story breaks those levers out in black and white.
Result: Fair Value of $9.83 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that upside story can break quickly if high R&D spend keeps net losses elevated, or if ABCL635 and partnered programs fail to deliver meaningful clinical progress.
Find out about the key risks to this AbCellera Biologics narrative.
Another Take On The Valuation
The narrative fair value suggests AbCellera looks cheap, but the market is telling a different story when you look at P/S. At 14.3x sales versus 2.9x for the US Life Sciences industry and 3.6x for peers, and a fair ratio of just 0.3x, the gap is very wide and points to meaningful valuation risk if sentiment cools.
This kind of disconnect between the narrative and the sales multiple raises a simple question for you: are expectations already running ahead of what the current business supports, or is the market still underestimating the long term payoff from the pipeline, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mix of optimism and concern running through this story, now is a good time to review the facts yourself and decide where you stand. You can start with 1 key reward and 2 important warning signs.
Looking for more investment ideas?
If AbCellera has you thinking more broadly about where to put your next dollar to work, now is the time to scan for other compelling setups before they move.
- Target income potential with companies that have 5% plus yields by checking out a curated group of 11 dividend fortresses.
- Hunt for quality at a discount by focusing on 59 high quality undervalued stocks that pair strong fundamentals with appealing price tags.
- Prioritize peace of mind by reviewing 72 resilient stocks with low risk scores built around resilient balance sheets and lower risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com